This is an open access article under the terms of the Creat ive Commo ns Attri butio n-NonCo mmercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. receptors, and metabolites, have been targeted by Abs or small molecules, but additional strategies are needed to fine-tune and optimize for augmenting antitumor effects restricted in the TME while avoiding systemic autoimmunity. Here, we provide a brief synopsis of these cells in cancer and how they can be controlled to achieve therapeutic outcomes. 
| INTRODUC TI ON
The identification of tumor antigens has led to various manipulations of the host immune system to treat cancer. 1 However, only a limited number of patients show antitumor effects, such as tumor regression, after multiple vaccinations despite the development of measurable humoral and cellular immune responses against tumor antigens. The immunosuppressive tumor microenvironment (TME)
is a critical barrier for the development and augmentation of effective antitumor immune responses. The immunosuppressive TME PD-ligand 1 (PD-L1). 6 Therefore, the focus of cancer immunology to develop effective cancer immunotherapies has shifted to understanding and controlling these immune suppressive networks in the TME.
Meth A (a 3′-methylcholanthrene-induced sarcoma)-bearing mice harbor immune suppressive CD4 + T cells, which are peripherally induced Treg cells. 7 There are also thymus-derived immune suppressive lymphocytes, which appear in autoimmune diseases caused by neonatal thymectomy. 8 
| CHAR AC TERIZ ATI ON OF TREG CELL S

Regulatory T cells were initially defined as CD4 + T cells with a high expression of CD25 (interleukin [IL]-2 receptor α-chain). The Foxp3
gene, a member of the Forkhead/winged-helix family of transcriptional regulators, was then discovered as a master regulator in developing Treg cells based on the following findings: Scurfy mice with a frameshift mutation in the Foxp3 gene have T cell inflammation in multiple organs and a lethal autoimmune disease because of effector T cell activation and increased cytokine production caused by the lack of Treg cells. 11 In addition, mutation of the Foxp3 gene in humans leads to IPEX syndrome (X-linked immune dysregulation, polyendocrinopathy, and enteropathy). 12 Table 1 and Figure 1 ). 19 Naive Treg cells that have recently left the thymus but have not been activated in the periphery possess weak suppressive activity.
After TCR stimulation in the draining lymph node, naive Treg cells the TME. 21 Thus, T cells need to be activated by APCs not only in the lymph node but also in the TME. Given that one important suppres- These Treg cells with tumor-specific TCRs were also detected in the periphery. 22 These findings suggest that tumor-specific activa- humans is 2%-5% in CD4 + T cells but increases to 10%-50% in the TME. What is the significance of Treg cell accumulation in the TME?
Treg cells are chemoattracted by chemokine gradients. 27 CCR4, CCR8, CCR10, and CXCR3 are chemokine receptors responsible for
Treg cell migration to the TME in response to CC and CXC chemokines: CCR4 is bound by CCL17 and CCL22, 28 CCR8 is bound by CCL1, 29 CCR10 is bound by CCL28, 30 and CXCR3 is activated by CXCL9/10/11. 31 Thymus-derived Treg cells preferentially recognize self-antigens by high-affinity TCR and clonally expand in the TME. In the TME, there are many tumor-associated self-antigens from dying tumor cells that are recognized by Treg cells rather than by effector and memory T cells. 32 Therefore, one can envisage that Treg cells are chemoattracted and recognize cognate antigens abundant in the TME, which leads to Treg cell activation and proliferation, contributing to the development of an immunosuppressive TME.
Immunosuppressive cytokines, such as TGF-β and IL-10, produced by tumor cells and immune cells in the TME also increase Treg cells. 
| TARG E TING TREG CELL S IN C AN CER IMMUNOTHER APY
The presence of a high number of Treg cells and a low ratio of CD8 + T cells to Treg cells in the TME are correlated with poor prognosis, which suggests that Treg cells suppress tumor antigen-specific T cell responses. 24 Therefore, depletion of Treg cells or the control of Treg cell functions could be promising immunotherapies.
Depletion of Treg cells increases antitumor immune responses
and contributes to tumor eradication in mouse models. Importantly, an initial study revealed that Treg cell depletion induced tumor regression in some tumor cell lines, such as Meth A and RL-male 1, but not in others, such as AKSL2 and RL-female 8. sponses were not observed in most patients. 49 Another concern is that systemic Treg cell depletion might increase the risk of immune- 
| Regulatory T cell depletion
Regulatory T cells in the TME express several cell surface markers including CD25, CTLA-4, PD-1, ICOS, GITR, OX40, CD15s, 52 CCR4, and CCR8, and these markers can be used to deplete Treg cells. 
| CD25
| Cytotoxic T-lymphocyte antigen-4
Cytotoxic T-lymphocyte antigen-4 is constitutively expressed by 
| OX40 and GITR
Other molecules, such as OX40, 59 GITR, 13 
| Chemokine and chemokine receptors
Regulatory T cell chemotaxis through CCL28-CCR10, CCL1-CCR8, and CCL22-CCR4 into the TME has been studied. Blocking chemokine and chemokine receptor interactions attenuates Treg cell accumulation into the TME, which increases antitumor immune responses. For example, hypoxia in the TME induces CCL28 expression and chemoattracts CCR10 + Treg cells. Intratumoral administration of anti-CCR10 immunotoxin, which blocks the interaction of CCL28 and CCR10, reduces Treg cell accumulation in the TME and increases the antitumor immune response in a mouse model. 64 Therefore, therapies that target CCL1-CCR8 molecules warrant testing in the clinic.
| Chemotherapy
Low doses of cyclophosphamide selectively inhibit Treg cell proliferation and induce Treg apoptosis. repeats that promotes the activation and secretion of TGF-β. 71 Increased GARP expression is observed in activated Treg cells, 72 and GARP could be a candidate for Treg cell control in preclinical studies. MDSCs in the TME.
| Tyrosine kinase inhibitors
| CD39 and CD73
CD39 and CD73 metabolize extracellular ATP to adenosine, which binds to A 2 AR and inhibits effector T-cell activation. Adenosine negatively signals to the APCs and attenuates activation of effector T cells. Regulatory T cells express both CD39 and CD73 at high levels, especially in the TME. 48 Thus, CD39 and CD73, which are critical to adenosine metabolism, are promising therapeutic targets and are currently under investigation in clinical trials.
| Vascular endothelial growth factor-vascular endothelial growth factor receptor axis
The vascular endothelial growth factor (VEGF)-VEGF receptor 2 (VEGFR2) pathway is involved in the accumulation of immature DCs, MDSCs, and Treg cells, and the attenuation of T cell infiltration.
82
Increased PD-L1 expression and increased CD8 + T cell infiltration are observed after treatment with ramucirumab, a fully humanized IgG1 anti-VEGFR2 mAb. In addition, a reduction of eTreg cell infiltration and PD-1 expression by CD8 + T cells is observed in TILs compared with that of PBMCs after ramucirumab-containing therapies.
Furthermore, VEGFA promotes VEGFR2 + eTreg cell proliferation, and this effect is inhibited by Ramucirumab. 23 Thus, targeting VEGFR2 molecules expressed by activated Treg cells or blocking the VEGF-VEGFR2 axis might contribute to tumor-shrinking through Treg cell inhibition. 
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